Related Experiment Videos
Beta-blockade in acute myocardial infarction
1Wythenshawe Hospital, Manchester, England.
Insights
Early beta-blockade treatment for acute myocardial infarction (MI) significantly reduces chest pain, infarct size, and mortality. This intervention is safe, cost-effective, and improves outcomes for eligible patients within 12 hours of symptom onset.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary heart disease is a leading cause of death.
- Acute myocardial infarction (MI) requires interventions to reduce myocardial oxygen demand.
Purpose of the Study:
- To evaluate the benefits of early beta-blockade in patients with acute MI.
- To assess the impact of beta-blockade on mortality, infarct size, and arrhythmias.
Main Methods:
- Intravenous followed by oral administration of beta-blockers within 12 hours of chest pain onset.
- Focus on beta 1-selective blockade, noting potential diminished benefit with intrinsic sympathomimetic activity (ISA).
Main Results:
- Significant reduction in chest pain and infarct size (approx. 30%).
- Decreased incidence of life-threatening ventricular arrhythmias, cardiac arrest, and reinfarction.
- About 15% reduction in vascular mortality at 1 week post-MI, sustained at 1 year.
Conclusions:
- Early intravenous, followed by oral, beta 1-selective blockade is a safe and effective treatment for acute MI.
- The intervention reduces mortality and improves patient outcomes, offering significant cost-effectiveness.
- Approximately 50% of eligible MI patients can benefit from this treatment.
Abstract:
Coronary heart disease is the most common cause of death in many Westernized countries. Patients who experience either a threatened myocardial infarction (MI) or an acute MI within the last 12 h or so can benefit from interventions that decrease myocardial oxygen demand. Beta-Blockade fulfills such a purpose mainly through diminishing the product of heart rate x systolic blood pressure. Added benefits of beta-blockade include (a) a redistribution of myocardial blood supply in favour of ischaemic areas, (b) inhibition of catecholamine-induced myocardial necrosis, and (c) a decrease in the Q-Tc interval and an increase in the threshold to ventricular fibrillation. Beta 1-Selective blockade is the essential ingredient; the possession of intrinsic sympathomimetic activity (ISA) may diminish benefit. Intravenous, followed by oral, beta-blockade within 12 h (preferably 6 h) of the onset of chest pain results in (a) a marked reduction in chest pain, (b) a reduction in infarct size by about 30%, (c) a diminished likelihood of threatened infarction progressing to overt infarction, (d) a reduction in the number of life-threatening ventricular arrhythmias, and (e) a reduction in the incidence of cardiac arrest and reinfarction. Intravenous, followed by oral, beta 1-selective blockade (atenolol) significantly reduces vascular mortality by about 15% at 1 week post-MI, and the benefit is maintained at 1 year. Such an intervention, provided contraindications to beta-blockade are respected, is safe and well tolerated. Probably about 50% of patients are eligible for such treatment. Such an approach is highly cost effective.